K2 Principal Fund’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

K2 Principal Fund’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-61,201	Closed	-$3.91K	–	357
2022 Q4	$3.91K	Buy	+61,201	New	+$2.34K	﹤0.01%	228

K2 Principal Fund's BIOTW Position: Q1 2023 in Review

K2 Principal Fund sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 61,201 shares — an estimated $3.91K sold.

K2 Principal Fund first reported a position in BIOTW in Q4 2022 and held it in 1 quarter. The position peaked at $3.91K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

K2 Principal Fund reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
K2 Principal Fund sold 61,201 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $3.91K.
K2 Principal Fund first reported a position in Biotech Acquisition Company Warrant in Q4 2022 and held it in 1 quarter.
K2 Principal Fund's Biotech Acquisition Company Warrant position peaked at $3.91K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on K2 Principal Fund's 13F filing for Q1 2023, filed 11 May 2023.